articleTop 1% cited
The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials
Arthritis & Rheumatism · 1993 · Vol. 36(6) · pp. 729–740
David T. Felson✉(American College of Rheumatology)Jennifer J. Anderson(American College of Rheumatology)Maarten Boers(American College of Rheumatology)Claire Bombardier(American College of Rheumatology)Miriam Chernoff(American College of Rheumatology)Bruce J. Fried(American College of Rheumatology)Daniel E. Fürst(American College of Rheumatology)Charles H. Goldsmith(American College of Rheumatology)Stephanie Kieszak(American College of Rheumatology)Robert W. Lightfoot(American College of Rheumatology)Harold E. Paulus(American College of Rheumatology)Peter Tugwell(American College of Rheumatology)Michael E. Weinblatt(American College of Rheumatology)Rudolph Widmark(American College of Rheumatology)H. James Williams(American College of Rheumatology)Frederick Wolfe(American College of Rheumatology)
Abstract
We propose a core set of outcome measures for RA clinical trials. We hope this will decrease the number of outcomes assessed and standardize outcomes assessments. Further, we hope that these measures will be found useful in long-term studies.
Rheumatoid Arthritis Research and TherapiesSpondyloarthritis Studies and TreatmentsAutoimmune and Inflammatory Disorders ResearchMedicineFace validityClinical trialPhysical therapyContent validityConstruct validityRheumatologyRheumatoid arthritisDiscriminant validityPatient-reported outcome
MeSH terms
Arthritis, RheumatoidClinical Trials as TopicHumansTreatment Outcome
Citations
1,640
FWCI
27.82
field-weighted impact
References
57
Percentile
100%
vs. same field & year
Citations per year
Cited by
Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis
Arthritis & Rheumatism · 1995 · 6,175 citations
Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
Arthritis & Rheumatism · 2003 · 1,756 citations
Preliminary definition of improvement in juvenile arthritis
Arthritis & Rheumatism · 1997 · 1,043 citations
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial
Arthritis & Rheumatism · 2004 · 1,168 citations
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
Arthritis & Rheumatism · 1998 · 971 citations
REMISSION IN A PROSPECTIVE STUDY OF PATIENTS WITH RHEUMATOID ARTHRITIS. AMERICAN RHEUMATISM ASSOCIATION PRELIMINARY REMISSION CRITERIA IN RELATION TO THE DISEASE ACTIVITY SCORE
Lara D. Veeken · 1995 · 376 citations
Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D)
Lara D. Veeken · 1997 · 849 citations
Treating rheumatoid arthritis to target: recommendations of an international task force
Annals of the Rheumatic Diseases · 2010 · 2,076 citations
References
Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score.
Annals of the Rheumatic Diseases · 1990 · 1,080 citations
Measuring health status in arthritis
Arthritis & Rheumatism · 1980 · 1,183 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.